icon-folder.gif   Conference Reports for NATAP  
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
VX-135, A Once-daily Nucleotide HCV Polymerase Inhibitor, Was Well Tolerated And Demonstrated Potent Antiviral Activity When Given With Ribavirin In Treatment-nave Patients With Genotype 1 HCV
  Reported by Jules Levin
AASLD Washington DC 2013, Nov 2-5
Serghei Popa1, Alina Berliba1, Nelea Ghicavii2, Alain A. Patat5, Robert S. Kauffman3, Julie Krop3, Varun Garg3, Myron Tong4, Sushmita M. Chanda6, Qingling Zhang6,
Christopher Westland6, Matthew W. McClure6, Leo Beigelman6, Lawrence M. Blatt6, John Fry6
1. Republican Clinical Hospital, Chisinau, Moldova, 2. Arensia Exploratory Medicine, Chisinau, Moldova, 3. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA.
4. Liver Center, Huntington Medical Research Institutes, Pasadena, CA, USA, 5. BioTrial, Rennes, France,6. Alios BioPharma Inc, South San Francisco, CA, USA








1. Wang, H-Y.; McGuigan, C. Future Medicinal Chemistry 2012, 4(5), 625-650.
2. Marcellin, P et al: ALS-2200, A novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-nave patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C. EASL Poster 866, April 2013.